HIV distal sensory polyneuropathy

Last reviewed 01/2018

  • estimated that 15% to 62% of patients with human immunodeficiency virus infection suffer from distal sensory polyneuropathy (DSP):
    • results either from HIV-associated immune and viral protein-mediated neurotoxicity or
    • from neurotoxic dideoxynucleoside antiretroviral therapy (ARV)
  • severe, chronic pain from HIV associated DSP
    • can have a profound negative effect on the physical, emotional, and functional health of the patient with HIV/AIDS
  • treatment options:
    • symptomatic
      • there is evidence regarding the efficacy of a high-concentration capsaicin patch reducing pain in patients with HIV neuropathy

Reference: